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EVALUATING INSURANCE APPROVAL RATES OF EXOME SEQUENCING AND
ITS EFFECT ON MINORITY PATIENTS’ ACCESS TO GENETIC CARE
Katlyn Renee Frane, B.S.
Advisory Professor: Chelsea Wagner, M.S., CGC

Exome sequencing (ES) is often a standard step in the genetic testing process
for patients with rare or complex disease. Despite clinical implementation of ES,
insurance companies (payers) continue to deny this test. We investigated if the payer
barrier is influenced by payer type, and if other demographic or clinical information
correlated to ES approval and obtainment. To do this, a retrospective chart and clinical
database review was completed on patients seen at a tertiary care center and
community-based clinic. Patient demographics, clinical indications, and testing
recommendations and outcomes were used to assess ES approval and obtainment.
We found that patients with a public payer were 91% less likely to have ES approved,
and 76% less likely to obtain ES compared to patients with a private payer. In our
cohort, all minority patients were more likely to have a public payer compared to white
patients. A consistent approach to ES recommendation was observed regardless of
patient demographic or clinical information. In conclusion, having a public payer
significantly impacts a patient’s ability to obtain ES and access the downstream
benefits of testing. Additionally, the public payer barrier disproportionately effects
minority patients as they are more likely to hold public payer options. Collectively, this
information can support the development of payer policies and initiatives that promote
equitable care of patients with rare diseases.
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INTRODUCTION
Patients with rare or complex conditions often experience what is known as a
diagnostic odyssey. A diagnostic odyssey refers to a patient enduring several tests and
evaluations from multiple providers to identify a cause for their condition. It is common
for patients to receive a genetic workup during this process, as many of these
conditions may be genetic in origin. A genetic evaluation typically involves a standard
genetic testing approach that is implemented across many medical genetics practices 1.
The testing approach varies slightly depending on the patient’s clinical presentation, but
typically starts with chromosome microarray, trinucleotide repeat studies, or a nextgeneration sequencing gene panel. Conventionally, 46% of patients receive a
diagnosis through this approach1. If these initial tests return negative, a more
exhaustive test such as exome sequencing (ES) may be utilized1. While previously
thought of as an experimental approach, ES has transitioned from a “new” clinical
technology to a standard, and often final, step in a genetic testing process. When
utilized appropriately, ES typically has a diagnostic yield between 25-35%2, 3. For
patients who obtained ES through a study at the Undiagnosed Disease Network (UDN),
61% of positive results were deemed clinically actionable3. For those patients with
negative ES, reanalysis within a year is shown to increase ES diagnostic yield by 11% 4.
Additionally, negative ES may allow patients to participate in additional research
studies or grant access to services like the UDN.
Many patients, however, are unable to obtain ES. Despite a standardized
approach to the use of ES in genetic practices with consistent clinically actionable
outcomes, only 50% of ES recommendations are approved by insurance companies
(payers) 5. Payers cite various reasons why ES is denied. These include lack of
1

preauthorization, indicating a patient does not fit testing criteria dictated by company
policy, failure to address ES in their current policies entirely, and citing ES as an
experimental procedure and/or not medically necessary3. Historically, private payers
are more likely to approve ES compared to public payers, but there is no guarantee of
ES coverage by holding a private policy versus a public one3, 6. These inconsistencies
between payers, and within a single payer policy, is one of the biggest problems facing
standard clinical implementation of ES7. Additionally, the out-of-pocket price for ES is
typically too expensive for patients to pay. Therefore, payer coverage is often
necessary to obtain ES, and lack of coverage may impede reaching potential
diagnoses8, 9.
When a standardized clinical approach is established, it is important to ensure
the implementation of that approach is equitable to all patients accessing the service.
However, there is evidence of racial-ethnic disparities in healthcare both outside and
within the realm of genetics. One example is a study that focused on lack of access to
mental health services from 2004-2012 for ethnic minorities. It found that during this
period the disparity was exacerbated rather than reduced. One of the main factors cited
as affecting this was type [private or public] of payer coverage, if any10. Within genetics,
it has been shown that Black women who are diagnosed with breast cancer receive
recommended testing at lower rates than White women. One of the conclusions was
having an employer-based [private] payer was an enabling factor for pursuing testing 11.
Other studies have also observed differences in payer coverage, noting that ethnic
minority groups, specifically Hispanic, Black, and Asian individuals, are more likely than
White individuals to hold Medicaid and Medicare12. Historically, publicly available
options are less likely to cover genetic testing3, 13.
2

Studies thus far have explored the diagnostic yield and clinical utility of ES,
identified that payers create barriers to obtaining ES, and that ethnic disparities exist in
healthcare. To date, the demographic and clinical information of individuals who have
received recommendations for ES, but do not obtain the test, have not been described.
We completed a retrospective study in a tertiary medical center aiming to characterize
ES approval rates dependent on the type of payer a patient has, and to determine
what, if any, demographic or clinical factors may correlate with ES approval and
obtainment. This will inform if payer approval or denial disproportionately affects
specific patient demographics, particularly minority, or nonwhite, patients.
Subsequently, this should inform payers and national organizations regarding the
formulation and support of policies promoting coverage of genetic services if current
policies result in inequitable distribution of care.

MATERIALS AND METHODS
Study Design
A retrospective review of clinical patient records was performed. Records were
from either an outpatient clinic associated with the University of Texas health Science
Center at Houston (UTHealth) academic medical center’s practice UTPhysicians, or a
provider-curated database of information on patients seen by UTHealth providers at a
local outpatient clinic that is associated with a publicly funded county health system.
This study qualified for exempt status by the University of Texas Health Science Center
Institutional Review Board (HSC-MS-20-0553).
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Participants
Reviewed records that resulted in the study cohort were from patients seen by
one of four medical geneticists at either clinic location from January 1 st, 2017 to Dec
31st, 2019. To be included in the study, patients must have received a recommendation
to pursue ES, ES reanalysis, or first tier genetic testing with ES as a reflex test at the
time of their appointment. Records of patients who had an explanatory diagnosis at the
time of visit, were seen at a specialty clinic or as an inpatient consult, had their ES
obtained through an outside provider, or were deceased prior to testing were
excluded.
A sub-cohort of patients (n=356) was generated based on payer decision for ES
(approved or denied) (Figure 1). ES decisions were categorized based on the following:
payer decision letter available for review; a provider or clinical staff note indicated payer
decision status; if ES results were available in the chart payer decision was categorized
as approved unless otherwise stated, and if results were not available, payer decision
was categorized as denied. A payer decision could not be determined for 95 patients.

4

Data
The following information was collected from eligible records using Qualtrics
software (v. June 2020, Qualtrics, Provo, UT): patient demographics including age,
race/ethnicity, sex, and payer type; tests, molecular or other, performed prior to ES and
those results; ES indication, year pursued, result, or why ES was not performed.
Statistics
Data was analyzed using the statistical analysis software program, STATA
(v13.1, College Station, TX). Statistical significance was set at p < .05. Descriptive
statistics including frequencies and percentages for categorical variables were
completed. Univariate logistic regression was employed to generate crude odd ratios
(OR) for different variables associated with various binary outcomes. Where
appropriate, multivariate logistic regression was used to generate an adjusted odds
ratio and to control for potential confounders between related variables for those same
outcomes.
RESULTS
Demographic and Clinical Information
During the designated study timeframe, 2,579 patients were seen at either clinic
location. Of these patients, 452 (17%) met the inclusion criteria for the study. Of the
cohort, 218 were Hispanic/Latino (48%), 277 held a public payer option (61%), and 272
were between the ages of 2 and 11 years (60%) (Table 1). The most prevalent
indications included dysmorphic/craniofacial features (55%), speech delay (48%), and
motor delay (38%). Common tests patients received prior to ES recommendation

5

included chromosome microarray (82%) and trinucleotide repeat disorder studies
(47%).

6

The number of tests ordered prior to ES recommendation was similar between
patients, irrespective of payer type or ethnicity/race (Figures 2, 3). Regarding payer,
minority patients held public payer options more frequently than White patients, and the
only patients with a community based financial assistance plan were Hispanic (Figure
4).

7
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Exome Sequencing Approval Based on Demographic and Clinical Information
Due to our interest in differences in payer approval, we grouped patients into a
sub-cohort where a payer decision could be classified (n=356). Of these patients, 159
(45%) had ES approved and 197 (55%) had ES denied. A higher percentage of
patients who had a private payer had their exome approved (81%), and a higher
percentage of patients with a public payer had ES denied (73%) (Figure 5).

Multiple demographic and clinical factors that could correlate with payer
decisions regarding ES approval were assessed. This initial analysis identified payer
type, ethnicity/race, age, and number of tests prior to ES as significantly associated
with ES approval (Table 2).

9

Clinic location was not significantly associated with ES approval. However, the
multivariate, adjusted regression model assessing these same variables revealed only
patients with a public payer (p <0.001) or who were African American/Black (p = 0.042)
were significant predictors of ES approval (Table 2). Specifically, patients with a public
payer were 91% less likely to have ES approved and African American/Black patients
62% less likely. When this analysis is performed without payer type, the only significant
variable associated with ES approval rates is ethnicity/race. Both Hispanic/Latino and
African American/Black patients (p <0.001) were less likely to have ES approved
(Table 3).
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Since payer type and ethnicity/race were significant in both the initial and
adjusted analyses, and because we observed minority patients holding a public payer
at a higher frequency, we compared those two variables. In the cohort, 413 individuals
held either a public or private payer option. In a separate regression analysis, it was
determined that of these individuals, all groups of minority patients were significantly
more likely to hold a public payer option than white patients (Table 4), (all p <0.001).

11

Exome Sequencing Obtainment
In the cohort, 187 (41%) patients obtained ES and 265 (58%), did not. Whether
ES was obtained did not always equate to ES being approved (Figure 6).
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For those who obtained ES, a lab program that existed during the time of the
study helped 20% of these patients obtain ES when they otherwise would not have
been approved by their payer to receive it or would not have been able to afford the
test. Some patients (2.6%) had ES approved but could not afford the out-of-pocket
price of the test. A logistical barrier, such as no blood draw being performed, was
encountered for 17% of patients who did not obtain ES. However, most patients (59%)
who did not obtain ES were not able to because their payer denied the test. Assessing
the demographic and clinical variables associated with obtainment as we did with
approval, we found the only significant variable associated with obtainment was payer
type (p <0.001). Patients with a public payer were 76% less likely to obtain ES (Table
5).
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Exome Sequencing Outcome
For those patients who obtained ES, 43 (23%) had a positive result (Figure 7).

A positive result included known or previously identified pathogenic or likely
pathogenic variants and variants of uncertain significance (VUS) that were clinically
determined to be causative of a patient’s phenotype. Of note, two patients that had a
positive result also had an American College of Medical Genetics (ACMG) secondary
finding reported14. Fifty-six (30%) patients had positive, non-diagnostic results, which
included findings clinically determined to be non-causative of a patient’s phenotype.
This included VUS, carriers for autosomal recessive conditions or possible familial
variants, and ACMG secondary findings (n =3). There were no variants identified for 88
(47%) patients.
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DISCUSSION
This study explores payer approval rates of exome sequencing and other
demographic or clinical factors associated with approval of and obtaining this test. In
our cohort, minority patients held a public payer option more frequently than other
payer types. This observation is consistent at a national level, given most individuals
who hold public insurance are either Hispanic/Latino or African American/Black 15. Our
data shows that all patients, regardless of ethnicity/race or payer type, were receiving
similar numbers of first tier tests, such as chromosome microarray, prior to ES. We
observed a diagnostic yield of 23% which falls within ranges previously reported 2, 3, 4,
adding confidence that our practice’s approach to genetic testing is appropriate and
consistent. Overall we found having a public payer significantly impacts ES approval
and obtainment, and this barrier disproportionately affects minority patients.
Payer Barrier Disproportionately Affects Minority Patients
In this study, we showed that individuals with a public payer are significantly less
likely to have ES approved or to ultimately obtain the test. Given minority patients hold
public payers more frequently than White patients, they are disproportionately affected
by the testing barrier introduced by public payer options. This is evidenced in our study
in that minority patients had ES denied at higher rates (164/197, 83%) and did not
obtain ES at higher rates (213/265, 80%) compared to White patients.
While having a public payer was identified as the driving factor for patients not
obtaining ES, African American/Black patients were significantly less likely to have ES
approved in our adjusted regression model. This may be a cohort effect as the number
of African American/Black patients in the study population was relatively small (n = 58;
15

13%) and most of these patients held a public payer resulting in significance during this
analysis. Comparatively, although our cohort was comprised mostly of Hispanic/Latino
patients (n=218; 48%), and they had mostly public payers, Hispanic/Latino patients
were not significant in the adjusted regression model. However, in the adjusted model
that excluded payer type, both Hispanic/Latino and African American/Black patients
were significantly less likely to have ES approved. It is likely that Asian/Asian
Indian/Middle Eastern and Other ethnicities were not significant because, while there
were increased odds they held a public payer compared to white patients, these odds
were much lower compared to Hispanic/Latino and African American/Black patients
and they made up a small portion of the cohort population. Other centers with a larger
Asian/Asian Indian/Middle Eastern population may wish to investigate further.
The barrier public payers introduce to the genetic testing process contributes to
a variety of impacts on patient care, explored below, all of which are therefore
experienced at a higher frequency in the minority patient population.
Public Payer Barrier and Missed Diagnoses
Having a diagnosis typically ends a patient’s diagnostic odyssey. While this may
be a subjective benefit to the patient, it is essential to the distribution of appropriate
care for patients and is often a gateway for necessary services. For example, a
diagnosis may reveal that a patient requires surveillance for symptoms that would not
have been assessed without the diagnosis. Similarly, a diagnosis can stop futile
surveillance unrelated to the diagnosis. Often, specialized school programs or assistive
services are not accessible without a known diagnosis. Once a condition is identified,
these resources become available to patients and their families in addition to necessary
16

funding support. Moreover, genetic counseling for the individual or family to explore the
psychosocial impacts of a diagnosis, provide anticipatory guidance on patient care,
discuss recurrence risks, familial testing, and family planning could occur. Families and
patients who have undergone ES report feeling relieved for having a diagnosis and
gratitude for having explored all possible diagnostic routes16, 17, 18. Using the observed
23% diagnostic yield in this study, in our cohort, there are potentially 61 patients
missing these benefits of a diagnosis, ~ 80% (n= 49) of whom are minorities.
While achieving a diagnosis is the main goal of ES, it is equally important to
recognize the benefits of a negative test result. Performing an initial ES allows patients
to pursue reanalysis to compare the patient’s results against newly available
information in the future. This is typically done one to two years after the first analysis
and has been shown to increase the diagnostic yield of the test4. Receiving negative
results may allow patients to qualify for additional testing or studies, as many of these
opportunities require participants to have had negative ES as an inclusion criterion.
Pursuit of reanalysis or participation in exploratory testing or studies may lead to a
diagnosis for patients. Interestingly, for one of our patients, a negative result
contributed to a diagnosis of exclusion. Further, patients have reported feeling less
worried when ES returns negative and physicians perceive negative results as not “yet”
having a diagnosis, but that result could change in the future19. ES may not always
result in a diagnosis, but these are examples of additional opportunities available to
patients who are able to obtain ES. In our cohort, 47% of patients who obtained ES had
a negative or normal result. This means, of the patients that did not obtain ES, there
are potentially 124 who are not eligible for these additional opportunities ~ 80% (n=99)
of whom are minorities.
17

ES occasionally results in unexpected, incidental findings, such as identifying a
VUS or an ACMG secondary finding14, 20. ACMG secondary findings may impact
patient care, however, they do not explain a patient’s phenotype, so they are nondiagnostic for the indication for testing. Specifically for VUSs, the phenotype of patients
who have them may contribute evidence of pathogenicity for the specific variant or may
open doors to interpretative family studies that could result in reclassification of the
variant. Psychosocially, however, patients report identifying a VUS as anxiety
provoking and difficult to navigate when trying to find a diagnosis16, 17. VUSs in known
disease-causing genes are particularly challenging as it can be hard for providers to
determine what interventions to implement, if at all, and reports indicate patients have
mixed interpretations of VUS depending on their life situation21.
Currently, minority patients are more likely to have a VUS identified on
expanded testing22, 23. This is due to African descent patients having higher rates of
polymorphic variants than white patients24, and genetic research and testing being
more readily available to White patient populations. This means more variants in White
patients have been classified and disease phenotypes are often based on these
individuals. Of our patients that obtained ES, 30% (56/187) had a positive, nondiagnostic result, 57% (32/56) of whom were minority patients. The barrier caused by
the increased likelihood of not being able to classify VUSs experienced by minority
patients means when ES is obtained, they are more likely to experience the
psychosocial impacts and challenges of identifying a VUS on testing. If more minority
patients were able to obtain ES, this number could decrease as genetic diversity is
introduced into the available information on genetic variants in databases and the
interpretation of those variants.
18

Public Payer Barrier Impact on Provision of Equitable Care
Providers may recognize ES is more accessible for patients with a private payer.
It is reasonable to predict that ES may be pursued earlier in the testing process for
these patients as it is a broader test. However, that was not observed for our practice
given our consistent genetic testing approach for all patients and only 17% (452/2,579)
of the patients seen from 2017 to 2019 received a recommendation to pursue ES.
A standardized genetic testing approach ensures patients are cared for
appropriately and equitably. However, care often becomes inequitable at the ES step
as many patients cannot obtain ES solely because they have a public payer. As a
result, providers exhaust their testing options to try to reach a diagnosis for their
patient. We see evidence for this in our data as a higher percentage of patients with
multiple tests had a public payer. This could be due to physicians attempting to “make
a case” for a patient needing ES by showing multiple other tests did not return a result,
or ES had been previously denied and the physician pursued additional, alternative
testing for the patient. Alternative testing often consists of ordering large panels that are
associated with a patient’s phenotype as panels are more frequently approved by
payers. This is supported by our data as 18% (47/265) of patients who had ES denied
pursued alternative testing. Of these individuals, 81% (38/47) had a public payer, and
only one alternative test resulted in a diagnosis for a patient. A previous study found
that up to 23% of patients who were diagnosed through ES would not have been if
traditional panel testing had been pursued25. This is evidence that ES, when
recommended, is the best and most appropriate next test for patients, and additional or
other tests are not sufficient alternatives. Public payers denying ES when it is
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recommended leaves patients in their diagnostic odyssey and affects providers’ ability
to provide appropriate and equitable care.
Limitations
There are limitations inherent to performing a retrospective chart review. Firstly,
patient demographics were recorded based on information available within patient
records and may not have been representative of the patient’s personal identification
as it was not always self-reported, rather, recorded during or after the patient’s
appointment. This is especially true regarding demographics such as race/ethnicity. To
account for this we used consistent sources for this demographic including the genetics
appointment note and/or pedigree, and the electronic medical record depicted
race/ethnicity. If the patients’ race/ethnicity was not available from these sources, or if
what was listed did not fit into the predetermined categories, the patient’s race/ethnicity
was categorized as “Other”.
Most of the cohort used for the multivariate analyses was generated under the
assumption that ES obtainment meant their payer had approved the test, and
conversely, that no ES available for review was equivalent to payer denial unless
otherwise stated. We mitigated the impact of this approach by creating the sub-cohort
to separate those individuals where this assumption appeared false before proceeding
with the multivariate analysis.
Further, we recognize there are additional barriers to patients receiving
appropriate genetic care, starting at the referral process. We were only able to assess
patients that made it physically to the genetic clinic when we know there are many
patients who are not referred, uninsured, or unable to attend their appointment. Finally,
20

our cohort represents a single medical genetics practice in a large, tertiary care center
in a particular region of the United States. Therefore, these findings may not be
reproducible in a different population or other areas of the country. We attempted to
address both of these concerns by inclusion of more than one clinical location, which
was shown to have no significant differences in study outcomes presented here.
Future Directions
We briefly explored the psychosocial impacts of ES results experienced by
patients16, 17, 19 ; however, there is limited information regarding the psychosocial impact
of patients who desire a specific test and are unable to obtain it. Understanding these
impacts may help a provider better advocate for patients in their testing process, and
potentially identify what barriers are the most psychosocially impactful to patients in the
molecular testing process.
Previous studies have explored what influences payer policy decisions3, 26;
however, additional research is needed in understanding the payer policy making
process so appropriate steps can be taken to provide evidence to inform the creation
and revision of those policies. Additionally, given our data shows public payers
contribute to inequitable care, it would be beneficial to see if these findings are
generalizable to other medical centers, potentially through a multi-center collaboration
replicating or expanding on the findings presented here.
Conclusions
Minority patient populations are disproportionately affected by the impacts of not
obtaining ES due to the higher likelihood of having a public payer coverage option.
Despite the best and equitable efforts of providers, missed diagnoses are a prevalent
21

secondary outcome of ES denial by public payers. The results of this paper contribute
to the growing body of literature recognizing payer barriers to genetic testing and
healthcare in general. Our findings illuminate the inequities in care that result from
public payers denying ES and should inform payer policies moving forward. ES has
graduated from an experimental last resort to a clinically useful gateway to additional
resources and options for patients in their diagnostic odyssey. Therefore, to promote
equitable care of patients with rare disease, payer policies and national organization
initiatives that support equal access to this impactful, diagnostic tool must be
established.
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